Since the last several decades have seen repetitive failures to develop Aβ- or tau-targeted therapies for AD, strategies besides decreasing fibril aggregation are gaining popularity, including APOE-targeted therapies. The gene discussed is MAPT; the disease is Alzheimer disease.